Keyphrases
Metformin
100%
Patients with Coronary Artery Disease
48%
Coronary Artery Disease
48%
Left Ventricular Hypertrophy
43%
Without Diabetes
40%
Left Ventricular Remodeling
40%
Heart Failure
40%
Cardiac Magnetic Resonance Imaging (cMRI)
30%
Dapagliflozin
27%
Placebo
26%
Patients with Heart Failure
23%
Epicardial Adipose Tissue
20%
Aortic Valve Stenosis
20%
Patients with Diabetes
20%
Randomized Controlled Trial
20%
Amino Acid Homeostasis
20%
Diabetes Status
20%
Anti-inflammatory Effect
20%
Disease-associated
20%
Metformin Therapy
20%
Sodium
20%
Cotransporter
20%
9p21 Locus
20%
Type 1 Diabetes Mellitus (T1DM)
20%
Left Ventricular Mass
18%
Insulin Resistance
18%
Metformin Treatment
14%
Regress
13%
Cardiovascular Disease
11%
Branched-chain Amino Acids
10%
Trial Registration
9%
Type II Inhibitor
8%
Systolic Blood Pressure
8%
Oxidative Stress
8%
Pre-diabetes (pre-DM)
8%
Diabetic Patients
8%
Cardiovascular Effects
8%
March 2015
8%
Antidiabetic Agents
8%
Non-diabetic
7%
Left Ventricular End-diastolic Volume (LVEDV)
7%
Risk Factors
6%
Type 2 Diabetes Mellitus (T2DM)
6%
Therapeutic Action
6%
Amino Acids
6%
Diabetes
6%
Insulin Resistance Index
6%
Fasting Insulin
6%
Randomized Placebo-controlled Trial
6%
Weight Loss
6%
Neutrophil-to-lymphocyte Ratio
6%
9p21
6%
Heart Failure Trials
5%
Double-blind Placebo-controlled Trial
5%
Pharmacology, Toxicology and Pharmaceutical Science
Metformin
100%
Coronary Artery Disease
49%
Congestive Heart Failure
44%
Heart Left Ventricle Hypertrophy
42%
Heart Ventricle Remodeling
40%
Placebo
36%
Dapagliflozin
25%
Diabetes Mellitus
22%
Antiinflammatory Activity
20%
Randomized Controlled Trial
20%
Amino Acid
20%
Ischemic Heart Disease
20%
Cotransporter
20%
Insulin Resistance
17%
Cardiovascular Disease
13%
Branched Chain Amino Acid
8%
Observational Study
6%
Non Insulin Dependent Diabetes Mellitus
6%
Cytokine
6%
Impaired Glucose Tolerance
5%
Antidiabetic Agent
5%
Medicine and Dentistry
Glycon
80%
Diabetes
62%
Coronary Artery Disease
49%
Left Ventricular Hypertrophy
40%
Adipose Tissue
22%
Cardiac Magnetic Resonance Imaging
22%
Diabetes Mellitus
22%
Congestive Heart Failure
22%
Randomized Controlled Trial
20%
Ischemic Heart Disease
20%
Antiinflammatory Activity
20%
Cotransporter
20%
Heart Ventricle Remodeling
20%
Insulin Resistance
17%
Placebo
14%
Cardiovascular System
13%
Cardiovascular Disease
11%
Neutrophil
6%
Lymphocyte
6%
Impaired Glucose Tolerance
5%
Systolic Blood Pressure
5%
Body Weight
5%
Oxidative Stress
5%
Antidiabetic Agent
5%
Dapagliflozin
5%
Observational Study
5%